Literature DB >> 32524269

miR-22 suppresses cell viability and EMT of ovarian cancer cells via NLRP3 and inhibits PI3K/AKT signaling pathway.

H Wu1, J Liu2, Y Zhang3, Q Li4, Q Wang5, Z Gu6.   

Abstract

PURPOSE: miR-22 plays a great role in inhibiting cell growth, metastasis and enhanced cell apoptosis in several cancers. The purpose of this study was to investigate the functions of miR-22 in ovarian cancer.
METHODS: The proliferative ability was measured using CCK-8 assay. The protein expression associated with EMT and PI3K/AKT signaling biomarkers were measured by western blot. Luciferase assay applied to measure the luciferase activity. Kaplan-Meier method was performed to evaluate the overall survival rate of ovarian cancers.
RESULTS: miR-22 was low expressed and NLRP3 was overexpressed in ovarian cancer tissues and cells, and downregulation of miR-22 was associated with poor prognosis. The expression of NLRP3 had a negative correlation with miR-22 expression in ovarian cancer. miR-22 promoted cell viability and EMT through directly binding to the 3'-UTR of NLRP3 mRNA and inhibited PI3K/AKT signaling pathway. NLRP3 partially restored functions of miR-22 on cell proliferation and EMT in ovarian cancer.
CONCLUSION: miR-22 impaired cell viability and EMT by NLRP3 and inhibited PI3K/AKT signaling pathway in ovarian cancer. The newly identified miR-22/NLRP3/PI3K/AKT axis provides novel insight into the pathogenesis of ovarian cancer.

Entities:  

Keywords:  EMT; Ovarian cancer; PI3K/AKT; Viability; miR-22

Year:  2020        PMID: 32524269     DOI: 10.1007/s12094-020-02413-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  6 in total

1.  Effects of miR-22 on viability, migration, invasion and apoptosis in retinoblastoma Y79 cells by targeting high-mobility group box 1.

Authors:  Min Liu; Shuo-Min Wang; Zheng-Xuan Jiang; Hennein Lauren; Li-Ming Tao
Journal:  Int J Ophthalmol       Date:  2018-10-18       Impact factor: 1.779

Review 2.  Elevated Adenosine Dehydrogenase (ADH) and Positive Tuberculin Test Firstly Misdiagnosed as Tuberculous Pleural Effusion Finally Proved as Pleural Mesothelial Sarcoma by Thoracoscopic Biopsy Pathology: a Case Report and Literature Review.

Authors:  Wen Q Li; Ai S Fu; Dong F Shao; Qian Zhang; Meng H Wang; Hong Y Wang; Yi Chen; Ci Zhang; Xiao Y Zhu; Yan L Ge
Journal:  Clin Lab       Date:  2019-10-01       Impact factor: 1.138

3.  Serum miR-22 may be a biomarker for papillary thyroid cancer.

Authors:  Deping Wang; Changxiu Guo; Tingting Kong; Guangxi Mi; Jiantao Li; Yuhan Sun
Journal:  Oncol Lett       Date:  2019-02-04       Impact factor: 2.967

4.  miRNA-20b inhibits cerebral ischemia-induced inflammation through targeting NLRP3.

Authors:  Jingru Zhao; Hebo Wang; Lipeng Dong; Sujuan Sun; Litao Li
Journal:  Int J Mol Med       Date:  2018-12-31       Impact factor: 4.101

5.  NLRP3 in human glioma is correlated with increased WHO grade, and regulates cellular proliferation, apoptosis and metastasis via epithelial-mesenchymal transition and the PTEN/AKT signaling pathway.

Authors:  Xiao-Feng Yin; Qiong Zhang; Zhuo-Yu Chen; Hai-Fang Wang; Xin Li; Hong-Xia Wang; Hai-Xia Li; Chun-Min Kang; Shuai Chu; Kai-Fei Li; Yao Li; Yu-Rong Qiu
Journal:  Int J Oncol       Date:  2018-07-12       Impact factor: 5.650

6.  MicroRNA-22 Suppresses Breast Cancer Cell Growth and Increases Paclitaxel Sensitivity by Targeting NRAS.

Authors:  Ying-Kui Song; Yang Wang; Yi-Yang Wen; Pei Zhao; Zhi-Jie Bian
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
  6 in total
  5 in total

Review 1.  The role of the inflammasome and its related pathways in ovarian cancer.

Authors:  Chenxi Liu; Xuemei Huang; Hongling Su
Journal:  Clin Transl Oncol       Date:  2022-03-14       Impact factor: 3.340

2.  Downregulated ADARB1 Facilitates Cell Proliferation, Invasion and has Effect on the Immune Regulation in Ovarian Cancer.

Authors:  Wei Zhu; Zhijie Xu; Meiyuan Huang; Xiang Wang; Xinxin Ren; Yuan Cai; Bi Peng; Qiuju Liang; Xi Chen; Yuanliang Yan
Journal:  Front Bioeng Biotechnol       Date:  2021-12-23

Review 3.  Targeting purine metabolism in ovarian cancer.

Authors:  Jingchun Liu; Shasha Hong; Jiang Yang; Xiaoyi Zhang; Ying Wang; Haoyu Wang; Jiaxin Peng; Li Hong
Journal:  J Ovarian Res       Date:  2022-08-13       Impact factor: 5.506

4.  Influencing Mechanism of Nod-Like Receptor Protein 3 Inflammasome Activation in A375 Cell Activity in Human Cutaneous Malignant Melanoma.

Authors:  Akebaier Sulaiman; Jin Lv; Junwei Fan; Reyila Abuliezi; Qian Zhang; Xuefeng Wan
Journal:  J Immunol Res       Date:  2022-07-15       Impact factor: 4.493

Review 5.  Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer.

Authors:  Sonia Missiroli; Mariasole Perrone; Caterina Boncompagni; Chiara Borghi; Alberto Campagnaro; Francesco Marchetti; Gabriele Anania; Pantaleo Greco; Francesco Fiorica; Paolo Pinton; Carlotta Giorgi
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.